These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. SmvA is an important efflux pump for cationic biocides in Klebsiella pneumoniae and other Enterobacteriaceae. Wand ME; Jamshidi S; Bock LJ; Rahman KM; Sutton JM Sci Rep; 2019 Feb; 9(1):1344. PubMed ID: 30718598 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Exposure to Octenidine in a Simulated Sink Trap Environment Results in Selection of Pseudomonas aeruginosa, Garratt I; Aranega-Bou P; Sutton JM; Moore G; Wand ME Appl Environ Microbiol; 2021 Apr; 87(10):. PubMed ID: 33674437 [TBL] [Abstract][Full Text] [Related]
8. Increased Usage of Antiseptics Is Associated with Reduced Susceptibility in Clinical Isolates of Hardy K; Sunnucks K; Gil H; Shabir S; Trampari E; Hawkey P; Webber M mBio; 2018 May; 9(3):. PubMed ID: 29844113 [TBL] [Abstract][Full Text] [Related]
10. Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection. White AN; Learman BS; Brauer AL; Armbruster CE Infect Immun; 2021 Sep; 89(10):e0017721. PubMed ID: 34280035 [TBL] [Abstract][Full Text] [Related]
11. [Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation]. Cernohorská L; Chvílová E Klin Mikrobiol Infekc Lek; 2011 Jun; 17(3):81-5. PubMed ID: 21780025 [TBL] [Abstract][Full Text] [Related]
12. Reduced Susceptibility of Proteus mirabilis to triclosan. Stickler DJ; Jones GL Antimicrob Agents Chemother; 2008 Mar; 52(3):991-4. PubMed ID: 18180352 [TBL] [Abstract][Full Text] [Related]
13. Copper affects virulence and diverse phenotypes of uropathogenic Proteus mirabilis. Huang WS; Lee YJ; Wang L; Chen HH; Chao YJ; Cheng V; Liaw SJ J Microbiol Immunol Infect; 2024 Jun; 57(3):385-395. PubMed ID: 38453541 [TBL] [Abstract][Full Text] [Related]
14. Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion. Jiang SS; Liu MC; Teng LJ; Wang WB; Hsueh PR; Liaw SJ Antimicrob Agents Chemother; 2010 Apr; 54(4):1564-71. PubMed ID: 20123999 [TBL] [Abstract][Full Text] [Related]
15. An investigation of the impact of triclosan adaptation on Proteus mirabilis clinical isolates from an Egyptian university hospital. Elekhnawy E; Sonbol F; Abdelaziz A; Elbanna T Braz J Microbiol; 2021 Jun; 52(2):927-937. PubMed ID: 33826115 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of Urease Enzyme Production and some Other Virulence Factors Expression in Proteus mirabilis by N-Acetyl Cysteine and Dipropyl Disulphide. Abdel-Baky RM; Ali MA; Abuo-Rahma GEAA; AbdelAziz N Adv Exp Med Biol; 2017; 973():99-113. PubMed ID: 28190143 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activities against biofilm formed by Proteus mirabilis isolates from wound and urinary tract infections. Wasfi R; Abd El-Rahman OA; Mansour LE; Hanora AS; Hashem AM; Ashour MS Indian J Med Microbiol; 2012; 30(1):76-80. PubMed ID: 22361765 [TBL] [Abstract][Full Text] [Related]
19. Contribution of the efflux pump AcrAB-TolC to the tolerance of chlorhexidine and other biocides in Wand ME; Darby EM; Blair JMA; Sutton JM J Med Microbiol; 2022 Mar; 71(3):. PubMed ID: 35324422 [No Abstract] [Full Text] [Related]
20. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis. Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]